Medidata Solutions ($MDSO) has hit a milestone in use of its clinical trials software. Kaketsuken, a vaccine maker, has become the first pharma in Japan to use certain combined capabilities of Medidata's software products, the New York-based software company said Monday.
Kaketsuken, also known as the Chemo-Sero-Therapeutic Research Institute, used Medidata's randomization and trial-supply management tool called "Balance" along with its flagship "Rave" software in a Phase II vaccine study to "reduce time, cost and risk," according to Medidata. The Japanese pharma group also plans to use the software products together in future studies.
Like some competitors, Medidata aims to provide drug developers with a software platform for their clinical trials, offering multiple products with that platform to handle the various aspects of clinical development. A part of the pitch is to save CROs and pharma groups from the hassles of managing software from many different vendors. Oracle ($ORCL), BioClinica ($BIOC) and Merge Healthcare ($MRGE) have similar ambitions with their packages of clinical trial software.
Medidata's cloud-based platform is designed to bring efficiency improvements throughout the trial process, and offers additional benefits with the use of multiple integrated applications," Glen de Vries, president of Medidata, said in a statement. "The efficiencies seen by Kaketsuken--rapid trial startup, easier user training and simplified site usage--will help ensure maximum trial quality and result in real benefit to patients."
- here's the release